Biosimilars
🛡️ Public data only — no PHI permitted on this instance.
Biosimilars Opportunity Analyzer
LoE waves · ASP+6% economics · provider margin capture · interchangeable status · competitive dynamics — 1,615 corpus deals
LoE Waves
10
Reference Sales
$80.5B
Annual Opportunity
$10.6M
Annual Margin
$69.7M
Weighted Y3 Adoption
45.1%
Interchangeable Bios
2
Active Classes
9
Corpus Deals
1,615
LoE Wave Schedule & Adoption Curves
| Reference Drug | Class | LoE Year | Sales ($B) | Biosimilars | Interchangeable | Price Decline | Y3 Adoption |
|---|---|---|---|---|---|---|---|
| Humira (adalimumab) | Anti-TNF (IBD/Rheum) | 2023 | $21.50 | 10 | YES | +60% | 45.0% |
| Stelara (ustekinumab) | IL-12/23 (IBD/Psoriasis) | 2025 | $10.80 | 5 | NO | +40% | 32.0% |
| Eylea (aflibercept) | Anti-VEGF (Ophthalmology) | 2025 | $9.40 | 3 | NO | +35% | 28.0% |
| Avastin (bevacizumab) | Anti-VEGF (Oncology) | 2019 | $7.20 | 4 | NO | +68% | 58.0% |
| Rituxan (rituximab) | Anti-CD20 (Oncology/Rheum) | 2018 | $6.10 | 4 | NO | +62% | 52.0% |
| Herceptin (trastuzumab) | HER2 (Oncology) | 2019 | $7.10 | 6 | NO | +65% | 55.0% |
| Neulasta (pegfilgrastim) | G-CSF (Oncology) | 2018 | $4.50 | 5 | NO | +72% | 62.0% |
| Remicade (infliximab) | Anti-TNF (IBD) | 2016 | $4.90 | 4 | NO | +58% | 48.0% |
| Lantus (insulin glargine) | Long-Acting Insulin | 2021 | $3.20 | 2 | YES | +78% | 75.0% |
| Prolia / Xgeva (denosumab) | RANK-L (Osteo/Onc) | 2025 | $5.80 | 3 | NO | +38% | 30.0% |
Per-Drug Economics — Reference vs Biosimilar
| Reference | Ref WAC/Dose | Bio WAC/Dose | ASP+6 Ref | ASP+6 Bio | Ref Margin/Dose | Bio Margin/Dose | Volume | Opportunity ($M) |
|---|---|---|---|---|---|---|---|---|
| Humira | $7,145.00 | $2,860.00 | $7,574.00 | $3,032.00 | $429.00 | $172.00 | 8,500 | $2.18 |
| Stelara | $25,600.00 | $15,360.00 | $27,136.00 | $16,282.00 | $1,536.00 | $922.00 | 1,250 | $0.77 |
| Eylea | $2,070.00 | $1,345.00 | $2,194.00 | $1,426.00 | $124.00 | $81.00 | 28,000 | $1.20 |
| Avastin | $4,815.00 | $1,540.00 | $5,104.00 | $1,632.00 | $289.00 | $92.00 | 18,500 | $1.70 |
| Rituxan | $12,415.00 | $4,715.00 | $13,160.00 | $4,998.00 | $745.00 | $283.00 | 6,200 | $1.75 |
| Herceptin | $7,420.00 | $2,600.00 | $7,865.00 | $2,756.00 | $445.00 | $156.00 | 4,800 | $0.75 |
| Neulasta | $6,985.00 | $1,955.00 | $7,404.00 | $2,072.00 | $419.00 | $117.00 | 12,500 | $1.46 |
| Remicade | $1,280.00 | $540.00 | $1,357.00 | $572.00 | $77.00 | $32.00 | 15,200 | $0.49 |
| Prolia / Xgeva | $1,250.00 | $775.00 | $1,325.00 | $822.00 | $75.00 | $47.00 | 9,500 | $0.27 |
Site-Level Adoption & Margin Capture
| Site Type | Biologic Volume | Adoption | Margin/Dose ($) | Annual Margin ($M) | Y3 Growth |
|---|---|---|---|---|---|
| Oncology Infusion Centers | 95,000 | 62.0% | $385.00 | $22.67 | +48.0% |
| Rheumatology Practice Infusion | 62,000 | 55.0% | $285.00 | $9.72 | +42.0% |
| GI / IBD Infusion Suites | 48,500 | 58.0% | $325.00 | $9.14 | +45.0% |
| Ophthalmology Intravitreal | 125,000 | 35.0% | $95.00 | $4.16 | +55.0% |
| Dermatology Biologics Clinic | 38,500 | 52.0% | $245.00 | $4.91 | +38.0% |
| Home Infusion Provider | 32,000 | 68.0% | $215.00 | $4.68 | +52.0% |
| Hospital Outpatient Dept (HOPD) | 148,000 | 45.0% | $165.00 | $10.99 | +32.0% |
| Specialty Pharmacy Dispensing | 98,000 | 72.0% | $48.00 | $3.39 | +58.0% |
FDA Interchangeable Designation Status
| Biosimilar | Reference | Interchangeable Date | States Auto-Sub | Notification | Impact |
|---|---|---|---|---|---|
| Cyltezo (adalimumab-adbm) | Humira | 2023-10-15 | 48 | none (auto-sub) | 5-8% market share capture from auto-sub |
| Semglee (insulin glargine-yfgn) | Lantus | 2021-07-28 | 50 | none | significant auto-sub impact on retail Rx |
| Rezvoglar (insulin glargine-aglr) | Lantus | 2023-11-16 | 48 | notify prescriber | moderate capture |
| Abrilada (adalimumab-afzb) | Humira | 2024-01-11 | 42 | notify prescriber | growing share |
| Hadlima (adalimumab-bwwd) | Humira | TBD 2025 | 0 | pending | awaiting decision |
| Wyost (denosumab-bbdz) | Xgeva | TBD | 0 | pending | not yet launched |
Class-Level Competitive Dynamics
| Class | Biosimilar Count | Y1 Erosion | Y3 Erosion | Leader Share Y3 | Negotiating Leverage |
|---|---|---|---|---|---|
| Anti-TNF | 10 | 18% | 58% | 32% | high (10 biosimilars) |
| Anti-VEGF Oncology | 4 | 22% | 68% | 42% | moderate |
| Anti-VEGF Ophthalmology | 3 | 12% | 35% | 52% | low (new wave 2025) |
| IL-12/23 | 5 | 15% | 40% | 48% | moderate (emerging) |
| Anti-CD20 | 4 | 25% | 62% | 38% | high |
| HER2 | 6 | 28% | 65% | 35% | high |
| G-CSF | 5 | 35% | 72% | 32% | very high |
| Long-Acting Insulin | 2 | 45% | 78% | 55% | moderate |
| RANK-L | 3 | 10% | 38% | 58% | low (new 2025) |
Biosimilars Thesis: 10 LoE waves representing $80.5B in reference-drug sales.
Weighted Y3 biosimilar adoption reaches 45.1% across the platform — driven by interchangeable status, payer formulary steering, and provider-economics alignment.
Provider economics: biosimilar margin per dose is typically 60-70% below reference in absolute terms (ASP+6% math) but provider still captures meaningful absolute margin — and volume grows as biosimilars expand access.
Total annual margin opportunity $69.7M across infusion/dispensing sites. Humira wave (2023 LoE, 10 biosimilars, 2 interchangeable) is the reference playbook;
Stelara (2025) and Eylea (2025) are the next-wave opportunities. Oncology and rheum/IBD infusion sites capture the largest absolute dollars.